Modeling of human tumor xenografts and dose rationale in oncology.
Xenograft models are commonly used in oncology drug development. Although there are discussions about their ability to generate meaningful data for the translation from animal to humans, it appears that better data quality and better design of the preclinical experiments, together with appropriate data analysis approaches could make these data more informative for clinical development. An approach based on mathematical modeling is necessary to derive experiment-independent parameters which can be linked with clinically relevant endpoints. Moreover, the inclusion of biomarkers as predictors of efficacy is a key step towards a more general mechanism-based strategy.
Monica
M
Simeoni
Giuseppe
G
De Nicolao
Paolo
P
Magni
Maurizio
M
Rocchetti
Italo
I
Poggesi
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy*; D023041:Xenograft Model Antitumor Assays